Advertisement Biocept, Clarient launch new breast cancer CTC test - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Biocept, Clarient launch new breast cancer CTC test

Biocept and Clarient, a GE Healthcare Company, have launched Biocept's breast cancer circulating tumor cell (CTC) test, OncoCEE-BR, performed on a blood sample in US.

OncoCEE-BR detects CTCs, which are rare, and determines the patient’s HER2 status by fluorescence in situ hybridization (FISH).

The companies will market and sell the OncoCEE-BR CTC test to hospitals, pathologists and medical oncologists.

Biocept will perform the test in its laboratory and results will be interpreted and reported by Clarient’s pathology group.

Clarient chief commercial officer Dave Daly said Biocept’s OncoCEE-BR is an important test for their oncology portfolio, and will help the oncology community progress towards more personalized cancer care.